Mi SciELO
Servicios Personalizados
Revista
Articulo
Indicadores
Citado por SciELO
Accesos
Links relacionados
Citado por Google
Similares en SciELO
Similares en Google
Compartir
Archivos de la Sociedad Española de Oftalmología
versión impresa ISSN 0365-6691
Resumen
PUERTO-HERNANDEZ, B. et al. Effect on ocular blood flow of Combigan® versus placebo in patients with ocular hypertension. Arch Soc Esp Oftalmol [online]. 2011, vol.86, n.2, pp.42-46. ISSN 0365-6691.
Purpose: This study was undertaken to compare the ocular haemodynamic effects of Combigan® versus placebo in patients with ocular hypertension (OHT). Methods: Thirty patients with OHT were included in a controlled, randomised, double blind study in two parallel groups; 15 were randomised to receive Combigan® and 15 to receive placebo for a period of 3 months. At baseline and at 3 months retrobulbar blood flowmeasurements of the ophthalmic artery (OA) and central retinal artery (CRA) were taken using colour Doppler imaging (CDI) ultrasound, concurrently with intraocular pressure (IOP). Results: Combigan® significantly reduced IOP after 3 months of treatment (P = 0.001), whereas placebo showed no significant change in IOP. The baseline haemodynamic parameters were similar between treatment and placebo groups. Patients treated with Combigan® showed a statistically significant decrease in CRA resistive index (P = 0.007). Conclusions: Patients treated for 3 months with Combigan® showed a significant decrease of CRA resistive index that could be explained by the decrease in IOP.
Palabras clave : Colour Doppler imagine; Ocular blood flow; Combigan®; Central retinal artery; Ophthalmic artery; Rresistive index.